A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized, double blind, placebo controlled trial of the use of pentoxifylline (oxpentifylline) for the treatment of recurrent mouth ulcers.
| Condition | Intervention |
|---|---|
|
Recurrent Aphthous Stomatitis |
Drug: Pentoxifylline (also known as oxpentifylline) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
- Reduction in the median pain score
- Reduction in the median ulcer size
- Reduction in the median ulcer number
- Reduction in the total number of episodes of ulceration (RAS)
- Change in global ulcer severity score
- Increase in the proportion of ulcer free days
- Difference in the proportion of ulcer free days (comparing trial v baseline)
- Side effect incidence
- Side effect type
| Estimated Enrollment: | 30 |
| Study Start Date: | June 1996 |
| Estimated Study Completion Date: | November 1998 |
There are few effective treatments for recurrent aphthous stomatitis (cancer sores, recurrent mouth ulcers). Most existing treatments are palliative topical treatments. Some systemic drugs e.g. steroids and thalidomide can suppress the recurrence of mouth ulcers but have serious long term side effects. Pentoxifylline (also known as oxpentifylline) has been used systemically for many years to treat peripheral vascular disease and has a good side effect profile. It shares several actions with thalidomide but does not share its serious side effects. Furthermore, some small scale, open label clinical studies have indicated it may be very effective in treating recurrent aphthous stomatitis (RAS). This study enrolled patients with RAS for which no underlying cause could be identified. Patients kept a diary of the pattern of their mouth ulcers for 60 days to confirm the pattern of ulceration and provide baseline data. Those still qualified for the study were then randomized to treatment with pentoxifylline 400mg three times daily or an identical placebo tablet three times daily for a further 60 days during which they continued to keep a daily ulcer diary. At the end of this period, treatment was stopped and they kept the daily ulcer diary for a further 60 days to identify if any benefit from the treatment was continued after ceasing treatment.
Eligibility| Ages Eligible for Study: | 16 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of minor recurrent aphthous stomatitis
- 2 or more mouth ulcers per month for more than 6
- No current treatment for oral ulceration or willing to stop treatment
- Age 16 to 65 years
Exclusion Criteria:
- Taking ketorolac, theophylline or anti-hypertensive medication except diuretics (contra-indicated in patients treated with pentoxifylline)
- Systemic diseases that contra-indicate the use of pentoxifylline i.e. pregnancy, hypotension, ischaemic heart disease, acute myocardial infarction, cerebral or occular hemorrhage, renal or hepatic failure, porphyria or allergy to pentoxifylline.
- Patients with an underlying deficiency state or systemic disease that could cause recurrent mouth ulcers e.g. iron, vitamin B12 or foliate deficience, coeliac disease, Crohn's disease, ulcerative colitis, Behcet's disease or Aids.
Contacts and Locations| United Kingdom | |
| University Dental Hospital of Manchester | |
| Manchester, United Kingdom, M15 6FH | |
| Principal Investigator: | Martin H Thornhill, MBBS, BDS | University of Sheffield School of Clinical Dentistry |
More Information
No publications provided by Central Manchester University Hospitals NHS Foundation Trust
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00315679 History of Changes |
| Other Study ID Numbers: | MHT01 |
| Study First Received: | April 18, 2006 |
| Last Updated: | April 18, 2006 |
| Health Authority: | United Kingdom: National Health Service |
Keywords provided by Central Manchester University Hospitals NHS Foundation Trust:
|
recurrent aphthous stomatitis recurrent mouth ulcers pentoxifylline clinical trial |
double blind placebo controlled randomized |
Additional relevant MeSH terms:
|
Stomatitis Stomatitis, Aphthous Mouth Diseases Stomatognathic Diseases Pentoxifylline Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Platelet Aggregation Inhibitors |
Hematologic Agents Therapeutic Uses Radiation-Protective Agents Protective Agents Physiological Effects of Drugs Vasodilator Agents Cardiovascular Agents Free Radical Scavengers Antioxidants |
ClinicalTrials.gov processed this record on May 21, 2013